Patents by Inventor Jan-Erik Lofroth
Jan-Erik Lofroth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7959947Abstract: A film coating composition suitable for use in coating pharmaceutical formulations comprising a) an acrylic polymer dispersion, e.g. an ethylacrylate/methylmethacrylate copolymer such as Eudragit NE30D, b) a surfactant, c) sodium stearyl fumarate, and d) a water-containing liquid useful for the achievement of controlled release from pharmaceutical formulations such as tablets, pellets, etc.Type: GrantFiled: January 22, 2002Date of Patent: June 14, 2011Assignee: AstraZeneca ABInventors: Arne Hölzer, Jan-Erik Löfroth, Staffan Schantz
-
Publication number: 20100291217Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: November 18, 2010Inventors: Jan-Erik Löfroth, Jonas Ödman
-
Publication number: 20100291216Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: November 18, 2010Inventors: Jan-Erik Löfroth, Jonas Ödman
-
Patent number: 7815938Abstract: A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.Type: GrantFiled: September 16, 2004Date of Patent: October 19, 2010Assignee: AstraZeneca ABInventors: Jan-Erik Löfroth, Staffan Schantz, Anders Welin, Lars Johan Pontus de Verdier Hjärtstam
-
Publication number: 20080095853Abstract: An oral solid pharmaceutical dosage form comprising an acid sensitive proton pump inhibitor (PPI) as single active drug, releasing the PPI in two separate pulses, one immediate and one delayed. The PPI is formulated into a core material in the form of pellets, which are coated i.a. with a combination of a delayed release modifying layer and a lag time controlling layer. The pellets are further provided with an enteric coating layer. The application also relates to processes for preparing the dosage forms as well as their use in the treatment of gastrointestinal diseases.Type: ApplicationFiled: November 2, 2005Publication date: April 24, 2008Inventors: Niclas Clemmensen, Jan-Erik Lofroth, Katrin Walter, Peter Wang, Martin Wikberg
-
Publication number: 20080003281Abstract: An oral solid pharmaceutical dosage form comprising an acid sensitive proton pump inhibitor (PPI) as single active drug, releasing the PPI in two separate pulses, one immediate and one delayed. The PPI is formulated into a core material in the form of tablets, which are coated i.a. with a combination of a delay release modifying layer and a lag time controlling layer that together achieves beneficial release properties. The tablets are further provided with an enteric coating layer. The application also relates to processes for preparing the dosage forms as well as their use in the treatment of gastrointestinal diseases.Type: ApplicationFiled: November 2, 2005Publication date: January 3, 2008Applicant: ASTRAZENECA ABInventors: Niclas Clemmensen, Jan-Erik Lofroth, Henrik Sahlen, Katrin Walter, Peter Wang, Martin Wikberg
-
Publication number: 20070031493Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: October 10, 2006Publication date: February 8, 2007Inventors: Jan-Erik Lofroth, Jones Odman
-
Publication number: 20050089574Abstract: A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.Type: ApplicationFiled: September 16, 2004Publication date: April 28, 2005Inventors: Jan-Erik Lofroth, Staffan Schantz, Anders Welin, Lars, Johan, , Hjartstam
-
Patent number: 6827947Abstract: A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.Type: GrantFiled: June 16, 2003Date of Patent: December 7, 2004Assignee: AstraZeneca ABInventors: Jan-Erik Löfroth, Staffan Schantz, Anders Welin, Lars Johan Pontus de Verdier Hjartstam
-
Publication number: 20040235727Abstract: The present invention provides, for example, a pharmaceutical formulation for oral administration comprising H 376/95, sodium dodecyl sulphate (SDS) and a polymer selected from the group comprising hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC) and polyoxyethylene oxide (PEO), a process for the preparation of such a formulation and the medical use of the formulation in the treatment of thromboembolism.Type: ApplicationFiled: March 19, 2004Publication date: November 25, 2004Inventors: Susanna Abrahmsen Alami, Anette Larsson, Jan-Erik Lofroth, Adam Rosinski
-
Publication number: 20040058001Abstract: A film coating composition suitable for use in coating pharmaceutical formulations comprising a) an acrylic polymer dispersion, e.g. an ethylacrylate/methylmethacrylate copolymer such as Eudragit NE30D, b) a surfactant, c) sodium stearyl fumarate, and d) a water-containing liquid useful for the achievement of controlled release from pharmaceutical formulations such as tablets, pellets, etc.Type: ApplicationFiled: July 11, 2003Publication date: March 25, 2004Inventors: Arne Holzer, Jan-Erik Lofroth, Staffan Schantz
-
Publication number: 20040022850Abstract: A pharmaceutical modified release formulation comprising a pharmacologically active substance and a modified water-soluble polysaccharide, which modified water-soluble polysaccharide is obtainable by: a) forming a precipitate of a water-soluble polysaccharide by contacting a solution of the water-soluble polysaccharide with a solvent in which the polysaccharide is poorly soluble or insoluble; or b) milling a water-soluble polysaccharide. The modified water-soluble polysaccharides provide modified release formulations with high tablet hardness. Also claimed are a process for preparing the modified release formulation, and the use of the modified water-soluble polysaccharides as an excipient in a pharmaceutical formulation.Type: ApplicationFiled: July 14, 2003Publication date: February 5, 2004Inventors: Marianne Eklund, Jan-Erik Lofroth, Urban Skantze
-
Patent number: 6673365Abstract: A new pharmaceutical formulation comprising the thrombin inhibitor HOOC—CH2—(R)-Cgl-Aze-Pab in combination with medium chain glycerides, a process for the preparation of such a pharmaceutical formulation, the use of a such formulation in the treatment of thromboembolism as well as a method of treating a patient in need of such a treatment by using said formulation.Type: GrantFiled: August 22, 1997Date of Patent: January 6, 2004Assignee: Astra AktiebolagInventors: Jan-Erik Löfroth, Lennart Lindfors, Anna-Lena Ungell
-
Publication number: 20030194440Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: October 24, 1997Publication date: October 16, 2003Inventors: JAN-ERIK LOFROTH, JONAS ODMAN
-
Patent number: 5795896Abstract: A new pharmaceutical formulation comprising the thrombin inhibitor HOOC--CH.sub.2 --(R)-Cgl-Aze-Pab in combination with one or more absorption enhancing agents, a process for the preparation of such a pharmacutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment and thromboembolism by using said formulation.Type: GrantFiled: December 18, 1995Date of Patent: August 18, 1998Assignee: Astra AktiebolagInventors: Jan-Erik Lofroth, Anna-Lena Ungell
-
Patent number: 5780062Abstract: The present invention is concerned with the formation of small particles of organic compounds by precipitating said organic compounds in an aqueous medium containing polymer/amphiphile complexes. The process is preferably used to prepare a readily soluble pharmaceutically active compound.Type: GrantFiled: November 27, 1995Date of Patent: July 14, 1998Assignee: The Ohio State University Research FoundationInventors: Sylvan Frank, Jan-Erik Lofroth, Levon Bostanian